Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Metagenomic analysis of fecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer

ABSTRACT: Metagenomic analysis of fecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer

PROVIDER: PRJEB10878 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR1018190_1.fastq.gz	Fastqsanger.gz
	ERR1018190_2.fastq.gz	Fastqsanger.gz
	ERR1018200_1.fastq.gz	Fastqsanger.gz
	ERR1018200_2.fastq.gz	Fastqsanger.gz
	ERR1018210_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 256

Similar Datasets

Identifying urinary RNA as non-invasive biomarkers for progression of chronic kidney disease

Project description:To identify urinary RNA as non-invasive biomarkers for progression of chronic kidney disease

2018-10-31 | GSE121978 | GEO

Identifying urinary RNA from prospective urine as non-invasive biomarkers for kidney transplant patients

Project description:To identify urinary RNA from prospective urine as non-invasive biomarkers for kidney transplant patients

2019-03-16 | GSE128347 | GEO

Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs

Project description:Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs

| PRJNA524343 | ENA

IMI MARCAR Project: towards novel biomarkers for cancer risk assessment

Project description:IMI MARCAR Project: towards novel biomarkers for cancer risk assessment

| PRJNA282585 | ENA

Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulate serum microRNA biomarkers

Project description:Liver biopsy is currently the only reliable method to establish non‐alcoholic fatty liver disease (NAFLD) severity. However, this technique is invasive and occasionally associated with severe complications. Thus, non‐invasive diagnostic markers for NAFLD are needed. Former studies have postulated 18 different serum biomarker microRNAs with altered levels in NAFLD patients. In this study, we have re‐examined the predictive value of these serum microRNAs and found that only 6 of them (miR‐34a, ‐192, ‐27b, ‐122, ‐197 and ‐30c) are validated in our independent cohort as biomarkers associated with NAFLD severity. Among them, miR‐192, ‐27b and ‐122 are abundantly expressed in liver and confidently detected in serum, and display strong correlations with transaminases. The classification performance of validated miRNAs (and their ratios) for patients with non‐alcoholic steatohepatitis (NASH) is similar to that reached by AST, whereas for advanced fibrosis prediction, the miR‐27b/‐197 ratio demonstrated a good performance and an excellent sensitivity and, along with the FIB‐4 index, may constitute a potent non‐invasive predictive tool.

2018-07-19 | GSE114923 | GEO

Identifying urinary RNA from biopsy associated urine as non-invasive biomarkers for kidney transplant patients

Project description:To identify urinary RNA from biopsy associated urine as non-invasive biomarkers for kidney transplant patients

2019-03-16 | GSE128348 | GEO

Non-Invasive Biomarkers for Diagnosing and Anticipating Post-Transplant Complications

Project description:Non-Invasive Biomarkers for Diagnosing and Anticipating Post-Transplant Complications

| PRJNA559412 | ENA

Non-Invasive Biomarkers for Diagnosing and Anticipating Post-Transplant Complications

Project description:Non-Invasive Biomarkers for Diagnosing and Anticipating Post-Transplant Complications

| PRJNA559410 | ENA

OCaMIR a non-invasive early diagnostic test for ovarian cancer: A multi-cohort retrospective and prospective analysis

Project description:Owing to the lack of effective screening tools and early detection biomarkers, ovarian cancer (OC) still remains as a deadly disease with highest mortality among other gynecological cancers. So far there have been no attempts to discover biomarkers using early stage OC patients. MicroRNAs (miRNAs) have been recognized as great tool to develop non-invasive biomarkers in various cancers including ovarian cancer.

2020-03-06 | GSE127873 | GEO

Identification of potential non-invasive biomarkers for diagnosing patients with methamphetamine use disorder

Project description:To date, diagnosis of methamphetamine use disorder (MUD) is based primarily on the patient’s self-reports of drug-seeking behaviour and interviews with psychiatrists in the absence of objective biomarkers. As an effective clinical method for diagnosis of MUD is still not available, the development of potential biomarkers for more accurate diagnosis is imperative. Transcription profiling and discovery of biomarkers in the treatment and recovery periods of MUD patients can be used as scientific basis to provide a greater understanding of the disease and to facilitate decisions on whether to continue or not. In this study, RNA sequencing analysis was performed to profile transcripts from hair follicle cells of healthy controls and patients with MUD, and biomarkers were discovered at each transition states to be used to diagnose MUD. This study will present an important information to diagnose MUD using non-invasive biomarkers for human addicts and it will help to develop better pharmacological treatment of MUD in the future.

2023-05-31 | GSE227204 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data